+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of LTD4 antagonists using QSAR



Development of LTD4 antagonists using QSAR



Agricultural Chemistry & Biotechnology 41(6): 477-482



In order to discover new Leukotriene D4 antagonists, Quantitative Structure-Activity Relationships (QSAR) were applied based on the known data. A series of chalcone derivatives were selected for the training set. A candidate was predicted using QSAR and synthesized, and its biological activity was tested.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010446857

Download citation: RISBibTeXText


Related references

Effects of combined receptor antagonists of leukotriene D4 (LTD4) and platelet-activating factor (PAF) on rhesus airway responses to LTD4, PAF and antigen. International Archives of Allergy and Applied Immunology 88(4): 462-470, 1989

Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists. Journal of Medicinal Chemistry 35(7): 1191-1200, 1992

Development of 3D-QSAR models for 5-lipoxygenase antagonists: Chalcones. Bioorganic & Medicinal Chemistry 10(12): 4035-4041, 2002

2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. Bioorganic and Medicinal Chemistry 17(14): 5198-5206, 2009

A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. Journal of Chemical Information and Modeling 46(5): 1984-1995, 2006

Synthesis and pharmacological evaluation of new 4- ethylbenzoic acids as LTD4-antagonists. European Journal of Medicinal Chemistry 35(4): 439-447, 2000

Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1H-tetrazole derivatives as angiotensin II receptor type 1 (AT1) antagonists. Bioorganic and Medicinal Chemistry Letters 23(16): 4540-4546, 2013

Inhibition by the LTD4 antagonist, SR2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions. Biochemical Pharmacology 38(14): 2291-2295, 1989

Reversal of exercise induced asthma by the ltd4 lte4 antagonists ly 171883. Journal of Allergy & Clinical Immunology 81(1): 315, 1988

Effect of a leukotriene D4 (LTD4) antagonist on LTD4 and ascaris antigen-induced airway responses in rhesus monkeys. International Archives of Allergy and Applied Immunology 86(4): 440-445, 1988

Structural requirements for induction of peroxisomal beta oxidation by leukotriene d4 ltd4 antagonists. FASEB Journal 2(5): ABSTRACT 4373, 1988

Competition of leukotrienes and ICI-198,615 for [3H]LTD4 binding sites in guinea pig lung membranes suggests the involvement of two LTD4 receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 258(2): 531-536, 1991

Prevention and reversal of aerosol LTD4-induced changes in guinea pig pulmonary mechanics by Wy-48252, an orally active LTD4/E4 receptor antagonist. International Archives of Allergy and Applied Immunology 89(1): 78-82, 1989

Novel leukotriene antagonists: structure activity of analogs of LTD4. Replacement of the 1-carboxylic group by a methyl group ("methyl principle") results in leukotriene antagonists and phospholipase inhibitors. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 17a: 519-525, 1987